Welcome to our dedicated page for Ufp Technologies news (Ticker: UFPT), a resource for investors and traders seeking the latest updates and insights on Ufp Technologies stock.
UFP Technologies Inc. reports developments for a contract development and manufacturing organization focused on single-use and single-patient medical devices. Company news commonly covers quarterly and annual results, non-GAAP measures such as adjusted EBITDA and adjusted EPS, program ramps, backlog commentary, acquisition integration, and manufacturing capacity tied to medical-device customers.
Updates also include customer supply agreements, new program launches, investor conference participation, and governance matters such as executive succession planning. The company's products and components are used across medical device, wound care, infection prevention, minimally invasive surgery, wearable, orthopedic soft-goods, and orthopedic implant-packaging applications.
UFP Technologies (NASDAQ: UFPT), a designer and manufacturer of medical device components and sterile packaging solutions, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.
The company will host a conference call at 10:00 AM Eastern Time on the same day to discuss the Q1 2025 results. Investors can join through:
- Toll-Free: 1-888-243-4451
- International: 1-412-542-4135
A live webcast will be available at www.ufpt.com, with a replay accessible afterward on the company's Investor Relations website at ufpt.com/investors/.
UFP Technologies (Nasdaq: UFPT), a specialized manufacturer focusing on medical market components and packaging, has announced its participation in the upcoming KeyBanc Capital Markets Healthcare Forum. The virtual event will feature presentations from the company's leadership, including Chairman and CEO R. Jeffrey Bailly and CFO Ron Lataille, scheduled for March 18, 2025, at 10:30 AM ET.
UFP Technologies (UFPT) reported record financial results for 2024, with net income rising 31.3% to $59.0 million and adjusted net income growing 32.5% to $67.6 million. Net sales increased 26.1% to $504.4 million compared to $400.1 million in 2023.
For Q4 2024, the company reported net income of $16.4 million (up 41.1%) and sales of $144.1 million (up 41.9%) compared to the same period in 2023. The company's MedTech segment showed particularly strong growth, with Q4 sales increasing 48.6% to $132.7 million and full-year sales rising 30.2% to $450.8 million.
CEO R. Jeffrey Bailly highlighted strong performance from newly acquired companies and noted expansion of operations in the Dominican Republic to accommodate business growth. The company anticipates two major programs launching in the second half of 2025 and expects strong cash flow to help reduce debt and position for future acquisitions.
UFP Technologies (Nasdaq: UFPT), a specialized manufacturer focusing on medical devices, sterile packaging, and engineered custom products, has announced its upcoming financial disclosure schedule. The company will release its fourth quarter and year-end 2024 financial results on Tuesday, February 25, 2025. This announcement pertains to the financial period ending December 31, 2024.
UFP Technologies (UFPT), a specialized manufacturer focusing on medical market components and packaging, has announced its participation in the CJS Securities 25th Annual "New Ideas for the New Year" Virtual Conference. The company's presentation is scheduled for January 14, 2025, at 8:45 AM ET.
Chairman and CEO R. Jeffrey Bailly and CFO Ron Lataille will represent the company at the conference, where they will present and host one-on-one investor meetings. The event provides an opportunity for investors to learn more about UFP Technologies' innovative designs and custom manufacturing capabilities in the medical sector.
UFP Technologies (UFPT) reported strong Q3 2024 results with net income increasing 40% to $16.4 million and sales growing 44% to $145.2 million compared to Q3 2023. The company's medical market sales rose 52.2% to $132.6 million, while gross margin improved to 28.6%. Organic sales growth was 9.7%, driven by strength in robotic surgery and infection prevention markets. Recent acquisitions performed above expectations, contributing $0.17 to EPS despite $3.1 million in increased interest expenses. The company's adjusted EBITDA increased 61.4% to $31.2 million in Q3 2024.
UFP Technologies, Inc. (Nasdaq: UFPT) has announced the acquisition of AQF Medical, a custom manufacturer of foam and thermoplastic components for medical devices and packaging. This marks UFP's fourth acquisition in recent months, expanding their MedTech platform and international presence. AQF Medical, headquartered in Navan, Ireland, with joint venture operations in Singapore, brings strategic value to UFP's global operations.
R. Jeffrey Bailly, Chairman and CEO of UFP Technologies, highlighted the acquisition's benefits, including an expanded European manufacturing presence and access to the Asian market. The companies share similar processes, materials, and clients, promising synergies and growth opportunities. Seamus Fagan, Managing Director of AQF Medical, expressed enthusiasm about joining UFP, anticipating mutual benefits for their worldwide client base.
UFP Technologies (UFPT) has announced its participation in the 15th Annual Midwest IDEAS Investor Conference, scheduled for August 28-29, 2024, in Chicago, IL. Chairman and CEO Jeffrey Bailly and CFO Ron Lataille will represent the company, with a presentation set for August 28 at 7:55 AM CT.
The event, hosted at The Gwen hotel, offers investors an opportunity to engage with UFPT executives through 1x1 meetings. The presentation will be webcast live and accessible via the conference website and UFP's investor relations page. This conference provides a platform for UFPT to showcase its business strategies and financial performance to potential investors and analysts in the Midwest region.
UFP Technologies (Nasdaq: UFPT) reported record Q2 2024 results, with net income of $13.6 million ($1.75 per diluted share), up from $11.9 million in Q2 2023. Sales increased 10.1% to $110.2 million. For the first half of 2024, net income reached $26.2 million on sales of $215.2 million.
The company completed three strategic acquisitions: Marble Medical, AJR Enterprises, and Welch Fluorocarbon, expected to add $90 million in revenue and $20 million in EBITDA. These acquisitions bring expertise in medical adhesives, patient handling, and thin film molding for implantable devices.
Q2 2024 highlights include:
- Medical market sales up 10.8% to $95.4 million
- Gross margin improved to 30.0%
- Operating income increased to $18.0 million
- Adjusted EBITDA grew 11.7% to $23.9 million